Febuxostat induced Stevens Johnson syndrome: A case report

Background: Febuxostat is a novel non-purine selective xanthine oxidase inhibitor with superior ability to lower serum urate levels than allopurinol. Case Report: We report a case of Stevens Johnson syndrome following febuxostat administration. Conclusion: This case report underlines the necessity of recognising this major mucocutaneous adverse reaction and the need for cautious medication usage.